Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial
Efficacy and safety in the Japan subset were generally consistent with outcomes in the DUO-E ITT population. This Japanese subset analysis of DUO-E supports carboplatin/paclitaxel + durvalumab followed by durvalumab with or without olaparib as new treatment options in patients with advanced or recurrent endometrial cancer and is the first to report on these regimens in Japanese patients alone.
Authors
- Tadaaki Nishikawa (ORCID: https://orcid.org/0000-0003-2606-4208)
- I Takaya
- Nobuhiro Kado (ORCID: https://orcid.org/0000-0002-6474-9796)
- Wataru Yamagami (ORCID: https://orcid.org/0000-0003-3925-6057)
- Shin Nishio (ORCID: https://orcid.org/0000-0003-2526-630X)
- Kazuhiro Takehara (ORCID: https://orcid.org/0000-0001-8808-3338)
- Tomoka Usami (ORCID: https://orcid.org/0009-0004-5742-6421)
- Shoji Kamiura (ORCID: https://orcid.org/0000-0002-5723-8891)
- Aikou Okamoto (ORCID: https://orcid.org/0000-0002-5079-0464)
- H. Kato
- Eiji Kondo (ORCID: https://orcid.org/0000-0001-9773-2520)
- Wataru Kudaka (ORCID: https://orcid.org/0000-0002-7600-074X)
- Hirokuni Takano (ORCID: https://orcid.org/0000-0002-6465-7883)
- Mayu Yunokawa (ORCID: https://orcid.org/0000-0001-7354-6977)
- Junzo Hamanishi (ORCID: https://orcid.org/0000-0002-7750-0623)
- Koji Nishino (ORCID: https://orcid.org/0000-0001-6218-8641)
- Yuichi Imai (ORCID: https://orcid.org/0000-0001-7347-9719)
- Toshiyuki Sumi (ORCID: https://orcid.org/0000-0002-7734-4173)
- Masahiko Mori (ORCID: https://orcid.org/0000-0003-3673-384X)
- Masahiro Nii
Institutions
- Kurume University (JP)
- Jikei University School of Medicine (JP)
- Mie University (JP)
- Keio University (JP)
- Kyoto University (JP)
- University of the Ryukyus (JP)
- Shizuoka Cancer Center (JP)
- National Hospital Organization Hokkaido Medical Center (JP)
- AstraZeneca (Japan) (JP)
- Aichi Cancer Center (JP)
- Jikei University Kashiwa hospital (JP)
- Shikoku Cancer Center (JP)
- National Cancer Center Hospital East (JP)
- Osaka International Cancer Institute (JP)
- University of the Ryukyus University Hospital (JP)
- Sapporo National Hospital (JP)
- Japanese Foundation For Cancer Research (JP)
- Ehime University (JP)
- Osaka Metropolitan University (JP)
- Tokyo Metropolitan University (JP)
- Niigata University (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Journal of Gynecologic Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.3802/jgo.2025.36.e118
- Citations
- 3
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.17
Funders
- AstraZeneca
- Sanofi
- Myriad Genetics
- Seagen
- Eisai
- Chugai Pharmaceutical